Progestin Regimen for Endometrial Hyperplasia Without Atypia
For endometrial hyperplasia without atypia, the levonorgestrel-releasing intrauterine system (LNG-IUS) is the preferred first-line treatment, with oral progestins as an alternative if LNG-IUS is not feasible.
Treatment Options and Dosing
The evidence strongly supports progestin therapy as the standard treatment for endometrial hyperplasia without atypia 1, 2, 1. The specific regimens include:
Preferred Option: LNG-IUS
- Levonorgestrel-releasing intrauterine device is superior to oral progestins, demonstrating higher regression rates (84-100%), lower recurrence rates, and fewer adverse events 3, 4
- This should be your first choice when medically appropriate
Alternative Oral Progestin Regimens
If LNG-IUS cannot be used, oral progestins are effective 3:
Medroxyprogesterone acetate (MPA):
- 15 mg daily, either cyclically (days 16-25 of cycle) for 10 days OR continuously 5
- Cyclic regimen shows comparable efficacy (90% regression) with better tolerability and patient acceptability compared to continuous dosing 5
Megestrol acetate:
Norethisterone acetate (NETA):
- 15 mg daily for 10 days (days 16-25 of cycle) 7
- Note: Dienogest 2 mg/day (days 10-25) shows superior regression rates (57.7% vs 37.9%) and lower persistence rates compared to NETA 7
Treatment Duration and Monitoring
Duration: Continue treatment for 6 months minimum 1, 3, 8
Monitoring protocol:
- Perform endometrial sampling (biopsy or D&C) every 6 months during treatment 1, 3
- Treatment should continue until two consecutive endometrial biopsies show no pathological changes 3
- For oral MPA specifically, 6-week continuous or 3-month cyclic regimens achieve >90% reversal rates 8
Key Clinical Considerations
When to escalate to hysterectomy:
- Progression to atypical hyperplasia
- Persistence of hyperplasia after 6-12 months of appropriate therapy
- Patient preference after failed medical management
- Note: Hysterectomy is not the preferred initial treatment for non-atypical hyperplasia 3
Important caveats:
- Screen for contraindications to progestin therapy: breast cancer, stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis, and active smoking 1
- LNG-IUS achieves 100% regression at 6 months compared to 64% with oral MPA, making it significantly more effective 4
- Cyclic MPA causes fewer side effects (less nausea, acne, menstrual changes) than continuous MPA while maintaining equivalent efficacy 5
Long-term follow-up:
- Continue surveillance even after successful regression, as recurrence can occur 3
- Patient education is critical for medication adherence and reducing recurrence rates 3
The evidence consistently demonstrates that progestin therapy effectively reverses endometrial hyperplasia without atypia in >90% of cases when properly administered and monitored 8. The choice between LNG-IUS and oral progestins should prioritize LNG-IUS when feasible, given its superior efficacy and tolerability profile.